Department of Pathology
540 E. Canfield Ave, Room 8200
Detroit, MI 48201
Leader of Proteases and Cancer Program of the Barbara Ann Karmanos Cancer Institute
Ph.D. (1986): Hebrew University, Jerusalem, Israel
1987-1990: National Institutes of Health, Bethesda, MD, USA, in the field of Tumor Biology
Matrix metalloproteinases, proteases, protease inhibitors, prostate cancer, and bone metastasis
1. Toth M, Hernandez-Barrantes S, Osenkowski P, Bernardo MM, Gervasi DC, Shimura Y, Meroueh O, Kotra LP, Galvez BG, Arroyo AG, Mobashery S, and Fridman R, 2002, Complex pattern of membrane type 1-matrix metalloproteinase shedding regulation by autocatalytic cell surface inactivation of active enzyme, J Biol Chem, 277: 26340-50.
2. Kruger A, Arlt M, Gerg M, Bernardo MM, Kopitz C, Chang M, Mobashery S and Fridman R, 2005, Antimetastatic activity of a novel mechanism-based gelatinase inhibitor, Cancer Res, 65: 3523-6.
3. Sun Q, Weber CR, Sohail A, Bernardo MM, Toth M, Zhao H, Turner JR, and Fridman R, 2007, MT6-MMP is highly expressed in human colon cancer, promotes tumor growth and exhibits unique biochemical properties, J Biol Chem, 282: 21998-2010.
4. Cho J-A, Osenkowski P, Zhao H, Kim S, Toth M, Cole K, Aboukameel A, Saliganan A, Schuger L, Bonfil RD, and Fridman R, 2008, The inactive 44-kDa processed form of MT1-MMP enhances proteolytic activity via regulation of endocytosis of active MT1-MMP, J Biol Chem, 283: 17391-405.
5. Sohail A, Sun Q, Zhao H, Bernardo MM, Cho J-A and Fridman R, 2008, MT4-(MMP17) and MT6-MMP (MMP25), a unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer, Cancer Met Rev, 27: 289-302.